Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Nuvalent (NUVL) with an Overweight rating and $116 price target The firm believes the company’s zidesamtinib has “best-in-class” potential in ROS1-positive non-small cell lung cancer. In addition, neladalkib’s safety supports differentiation in ALK-positive lung cancer, the analyst tells investors in a research note. Wells is a buyer of Nuvalent shares ahead of the two potential FDA approvals in the next 12-18 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target
- Nuvalent price target raised to $138 from $132 at UBS
- Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones
- Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
- Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)